1-8 of 8
Jeffrey S. Ross
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B091: Vulvar squamous cell carcinoma: Comprehensive genomic profiling of HPV(+) versus HPV(–) forms reveals a different set of potentially actionable biomarkers

Free
Erik A Williams, Adrienne J Werth, Meagan Montesion, Ethan S Sokol, Dean C Pavlick, Nikunj A Shah, Jo-Anne Vergilio, Natalie A Danziger, Jonathan K Killian, Douglas A Lin, Vincent A Miller, Jeffrey S Ross, Julia A Elvin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B091.
https://doi.org/10.1158/1535-7163.TARG-19-B091
Published: 01 December 2019
View articletitled, Abstract B091: Vulvar squamous cell carcinoma: Comprehensive genomic profiling of HPV(+) versus HPV(–) forms reveals a different set of potentially actionable biomarkers
Journal Articles

Abstract A80: Clinical evaluation of patients with advanced solid tumors harboring ERBB2-somatic mutations

Free
Sharon Wesley Dev Sahadevan, Zachary Chalmers, Garret M. Frampton, Navneet Dhillon, Kim Kramer, Philip J. Stephens, George W. Daneker, Jeffrey S. Ross, Vincent A. Miller, Maurie Markman, Siraj M. Ali, Ricardo H. Alvarez
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A80.
https://doi.org/10.1158/1535-7163.TARG-15-A80
Published: 01 December 2015
View articletitled, Abstract A80: Clinical evaluation of patients with advanced solid tumors harboring ERBB2-somatic mutations
Journal Articles

Abstract B194: Tivantinib in combination with erlotinib vs erlotinib alone for EGFR mutant NSCLC: Subgroup results from the phase 3 MARQUEE study

Free
Giorgio V. Scagliotti, Sergey Orlov, Joachim von Pawel, Frances A. Shepherd, Wallace Akerley, Jeffrey S. Ross, Dale Shuster, Qiang Wang, Brian Schwartz, Reinhard von Roemeling
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B194.
https://doi.org/10.1158/1535-7163.TARG-15-B194
Published: 01 December 2015
View articletitled, Abstract B194: Tivantinib in combination with erlotinib vs erlotinib alone for EGFR mutant NSCLC: Subgroup results from the phase 3 MARQUEE study
Journal Articles

Abstract A79: Comprehensive genomic profiling (CGP) of adult granulosa cell tumors (aGCT) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options

Free
Michelle Rowland, Scott McMeekin, Kathleen Moore, Mark Bailey, Siraj M. Ali, Rosemary Zuna, Jo-Anne Vergilio, James Suh, Juliann Chmielecki, Garrett M. Frampton, Doron Lipson, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, Julia A. Elvin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A79.
https://doi.org/10.1158/1535-7163.TARG-15-A79
Published: 01 December 2015
View articletitled, Abstract A79: Comprehensive genomic profiling (CGP) of adult granulosa cell tumors (aGCT) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
Journal Articles

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Free
Funda Meric-Bernstam, Garrett M. Frampton, Jaime Ferrer-Lozano, Roman Yelensky, Jose A. Pérez-Fidalgo, Ying Wang, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Xiaoping Su, Pilar Eroles, Juan Antonio Barrera, Octavio Burgues, Ana M. Lluch, Xiaofeng Zheng, Aysegul Sahin, Philip J. Stephens, Gordon B. Mills, Maureen T. Cronin, Ana M. Gonzalez-Angulo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (5): 1382–1389.
https://doi.org/10.1158/1535-7163.MCT-13-0482
Published: 05 May 2014
View articletitled, Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Open the PDF for Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR04: BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Free
Katherine Hutchinson, Doron Lipson, Philip J. Stephens, Geoff Otto, Pamela L. Lyle, Cindy L. Vnencak-Jones, Jeffrey S. Ross, Jeffrey A. Sosman, Igor Puzanov, Vincent A. Miller, William Pao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): PR04.
https://doi.org/10.1158/1535-7163.TARG-13-PR04
Published: 01 November 2013
View articletitled, Abstract PR04: BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Journal Articles

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner

Free
Fatima Cardoso, Virginie Durbecq, Jean-François Laes, Bassam Badran, Laurence Lagneaux, Françoise Bex, Christine Desmedt, Karen Willard-Gallo, Jeffrey S. Ross, Arsène Burny, Martine Piccart, Christos Sotiriou
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (12): 3042–3051.
https://doi.org/10.1158/1535-7163.MCT-06-0104
Published: 15 December 2006
View articletitled, Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner
Open the PDF for Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner in another window
Journal Articles

Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

Free
Jordi Codony-Servat, Maria A. Tapia, Marta Bosch, Cristina Oliva, Josep Domingo-Domenech, Begoña Mellado, Mark Rolfe, Jeffrey S. Ross, Pere Gascon, Ana Rovira, Joan Albanell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (3): 665–675.
https://doi.org/10.1158/1535-7163.MCT-05-0147
Published: 16 March 2006
View articletitled, Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
Open the PDF for Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells in another window